New York State Teachers Retirement System Sells 23,805 Shares of Elanco Animal Health Incorporated $ELAN

New York State Teachers Retirement System lessened its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 8.2% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 267,250 shares of the company’s stock after selling 23,805 shares during the period. New York State Teachers Retirement System owned about 0.05% of Elanco Animal Health worth $6,395,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in ELAN. NewEdge Advisors LLC boosted its position in Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after buying an additional 627 shares in the last quarter. Root Financial Partners LLC raised its stake in shares of Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after acquiring an additional 592 shares during the last quarter. Uniplan Investment Counsel Inc. bought a new position in shares of Elanco Animal Health in the fourth quarter valued at approximately $41,000. Torren Management LLC acquired a new position in shares of Elanco Animal Health in the 4th quarter worth approximately $46,000. Finally, Farther Finance Advisors LLC grew its position in Elanco Animal Health by 43.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,089 shares of the company’s stock worth $70,000 after acquiring an additional 938 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Price Performance

Elanco Animal Health stock opened at $24.64 on Wednesday. The business’s 50-day simple moving average is $23.29 and its 200 day simple moving average is $23.73. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. The stock has a market cap of $12.31 billion, a price-to-earnings ratio of -49.28, a P/E/G ratio of 1.64 and a beta of 1.68. Elanco Animal Health Incorporated has a 12-month low of $13.39 and a 12-month high of $27.72.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The company’s revenue was up 14.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, research analysts anticipate that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, CEO Jeffrey N. Simmons acquired 4,971 shares of Elanco Animal Health stock in a transaction on Friday, May 15th. The shares were purchased at an average cost of $20.09 per share, with a total value of $99,867.39. Following the completion of the purchase, the chief executive officer owned 171,971 shares in the company, valued at $3,454,897.39. The trade was a 2.98% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Rajeev A. Modi bought 4,911 shares of the stock in a transaction on Friday, May 15th. The shares were acquired at an average cost of $20.35 per share, with a total value of $99,938.85. Following the acquisition, the insider directly owned 160,812 shares in the company, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 1.14% of the company’s stock.

Wall Street Analysts Forecast Growth

ELAN has been the subject of several research analyst reports. Weiss Ratings downgraded Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Wall Street Zen downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. Citigroup raised their price objective on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, UBS Group reiterated a “buy” rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $28.55.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.